There’s a good chance you’ve heard about Ozempic, the season’s hottest new weight-loss medicine, which, according to a recent feature in New York Magazine, has “all the gays at CAA… shitting their brains out” and slimming down to size zero.
Like any miracle treatment that achieves public popularity, there are still skeptics and believers, but at least one major corporation, WeightWatchers, has decided to support the medication. On Monday, the Wall Street Journal reported that the leading weight management firm is acquiring Sequence, a telemedicine subscription service that allows doctors to prescribe both Ozempic and Wegovy.
According to the company’s chief executive, Sequence will be marketed to WeightWatchers’ more than four million subscribers. “There is genuine optimism over the health benefits of these drugs,” Sima Sistani explained. Aside from the side effects (nausea, vomiting, diarrhea, and constipation) and the fact that patients tend to gain all the weight back as soon as they stop taking Ozempic, the recent surge of interest in the drug has sparked fears of a type 2 diabetes medicine scarcity.